XKRX
053030
Market cap380mUSD
Jul 29, Last price
17,090.00KRW
1D
0.29%
1Q
10.26%
Jan 2017
0.83%
IPO
182.95%
Name
Binex Co Ltd
Chart & Performance
Profile
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 130,050,546 -16.00% | 154,824,776 -1.18% | 156,677,024 16.58% | |||||||
Cost of revenue | 146,239,960 | 153,285,038 | 126,125,354 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (16,189,414) | 1,539,737 | 30,551,670 | |||||||
NOPBT Margin | 0.99% | 19.50% | ||||||||
Operating Taxes | (3,747,349) | 311,129 | 2,868,264 | |||||||
Tax Rate | 20.21% | 9.39% | ||||||||
NOPAT | (12,442,065) | 1,228,608 | 27,683,406 | |||||||
Net income | (35,070,821) -850.86% | 4,670,748 -62.47% | 12,444,530 -34.83% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (12,000,000) | |||||||||
BB yield | 4.13% | |||||||||
Debt | ||||||||||
Debt current | 61,176,330 | 47,928,780 | 54,619,479 | |||||||
Long-term debt | 11,022,939 | 12,332,550 | 3,065,087 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 688,902 | 754,767 | 1,257,563 | |||||||
Net debt | 15,506,852 | 16,378,763 | (29,370,108) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (9,425,559) | 3,777,777 | 17,062,098 | |||||||
CAPEX | (10,366,068) | (7,747,267) | (36,453,163) | |||||||
Cash from investing activities | (2,853,403) | (14,179,951) | (39,124,800) | |||||||
Cash from financing activities | 29,840,754 | (12,573,199) | 3,223,216 | |||||||
FCF | (8,769,235) | (19,765,928) | 7,273,392 | |||||||
Balance | ||||||||||
Cash | 27,793,022 | 13,453,694 | 38,203,107 | |||||||
Long term investments | 28,899,394 | 30,428,873 | 48,851,566 | |||||||
Excess cash | 50,189,889 | 36,141,328 | 79,220,822 | |||||||
Stockholders' equity | 37,294,860 | 62,598,481 | 63,525,945 | |||||||
Invested Capital | 210,804,866 | 199,445,975 | 182,968,319 | |||||||
ROIC | 0.64% | 15.03% | ||||||||
ROCE | 0.65% | 12.14% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 30,918 | 32,497 | 30,925 | |||||||
Price | 18,340.00 104.92% | 8,950.00 -22.51% | 11,550.00 -24.01% | |||||||
Market cap | 567,041,567 94.96% | 290,845,751 -18.57% | 357,178,391 -24.46% | |||||||
EV | 582,794,586 | 317,272,276 | 328,485,409 | |||||||
EBITDA | (3,757,227) | 10,520,412 | 38,852,585 | |||||||
EV/EBITDA | 30.16 | 8.45 | ||||||||
Interest | 2,296,389 | 2,061,625 | ||||||||
Interest/NOPBT | 6.75% |